These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21434838)

  • 1. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
    Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
    Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.
    Rancoule C; Viaud M; Gres S; Viguerie N; Decaunes P; Bouloumié A; Langin D; Bascands JL; Valet P; Saulnier-Blache JS
    Biochim Biophys Acta; 2014 Jan; 1841(1):88-96. PubMed ID: 24120919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of lysophosphatidic acid pathway modulators as therapies for fibrosis.
    Budd DC; Qian Y
    Future Med Chem; 2013 Oct; 5(16):1935-52. PubMed ID: 24175745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
    Llona-Minguez S; Ghassemian A; Helleday T
    Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis.
    Rancoule C; Dusaulcy R; Tréguer K; Grès S; Attané C; Saulnier-Blache JS
    Biochimie; 2014 Jan; 96():140-3. PubMed ID: 23639740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials.
    Lin YH; Lin YC; Chen CC
    Cells; 2021 Jun; 10(7):. PubMed ID: 34209775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.
    Volkmann ER; Denton CP; Kolb M; Wijsenbeek-Lourens MS; Emson C; Hudson K; Amatucci AJ; Distler O; Allanore Y; Khanna D
    Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 39009409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
    Im DS
    Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists.
    Sidduri A; Budd DC; Fuentes ME; Lambros T; Ren Y; Roongta V; Schoenfeld RC; Gillespie P; Stevenson CS; Truitt T; Qian Y
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4450-4454. PubMed ID: 25155385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.
    Willier S; Butt E; Grunewald TG
    Biol Cell; 2013 Aug; 105(8):317-33. PubMed ID: 23611148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid and renal fibrosis.
    Pradère JP; Gonzalez J; Klein J; Valet P; Grès S; Salant D; Bascands JL; Saulnier-Blache JS; Schanstra JP
    Biochim Biophys Acta; 2008 Sep; 1781(9):582-7. PubMed ID: 18455518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LPA1 receptor activation promotes renal interstitial fibrosis.
    Pradère JP; Klein J; Grès S; Guigné C; Neau E; Valet P; Calise D; Chun J; Bascands JL; Saulnier-Blache JS; Schanstra JP
    J Am Soc Nephrol; 2007 Dec; 18(12):3110-8. PubMed ID: 18003779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of silicosis formation by lysophosphatidic acid and its receptors.
    Cong C; Mao L; Zhang Y; Zhao Z; Xu X; Zhao J
    Exp Lung Res; 2014 Sep; 40(7):317-26. PubMed ID: 24926730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids and eicosanoids in fibrosis: emerging targets for therapy.
    Castelino FV
    Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells.
    Ren Y; Guo L; Tang X; Apparsundaram S; Kitson C; Deguzman J; Fuentes ME; Coyle L; Majmudar R; Allard J; Truitt T; Hamid R; Chen Y; Qian Y; Budd DC
    Microvasc Res; 2013 Jan; 85():59-67. PubMed ID: 23084965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of anticancer lysophosphatidic acid agonists and antagonists.
    Parrill AL
    Future Med Chem; 2014 May; 6(8):871-83. PubMed ID: 24962280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic Acid Signaling in Diabetic Nephropathy.
    Lee JH; Kim D; Oh YS; Jun HS
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
    Liu W; Hopkins AM; Hou J
    Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid.
    Hama K; Aoki J
    Prog Lipid Res; 2010 Oct; 49(4):335-42. PubMed ID: 20230855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
    Okudaira S; Yukiura H; Aoki J
    Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.